Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor

  • Authors:
    • Patricia J. McLaughlin
    • Ian S. Zagon
  • View Affiliations

  • Published online on: June 1, 2006     https://doi.org/10.3892/ijo.28.6.1577
  • Pages: 1577-1583
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Opioid growth factor (OGF) is a native opioid peptide ([Met5]-enkephalin) that interacts with the OGF receptor (OGFr). OGF serves as a tonically active negative growth factor in neoplasia, and the OGF-OGFr axis contributes to the maintenance of an equilibrium in cell proliferation by targeting the cyclin-dependent inhibitory kinase pathway. To inquire whether the expression of OGFr is related to tumor progression, cell lines of human squamous cell carcinoma of the head and neck (SCCHN) were transplanted into nude mice, and small, medium, and large tumors were assessed for OGFr by receptor binding assays and quantitative immunohistochemistry, and for gene expression of OGFr mRNA. Large tumors had a reduction of 3- to 7-fold in OGFr binding sites relative to small tumors, and medium size tumors showed a progressive diminishment in OGF receptors that ranged between that of small and large neoplasias. Tumors with xenografts of three different cell lines of SCCHN, representing poorly- and well-differentiated cancers, exhibited similar results. Quantitative densitometric immunohistochemistry revealed data comparable to receptor binding assays. Receptor affinity and the gene expression of OGFr mRNA were unchanged in tumors of different sizes. These data demonstrate that OGFr is reduced in SCCHN with tumor progression and that translation/posttranslation of OGFr protein, but not transcriptional levels of the OGFr gene, is (are) involved. The attenuated levels of OGFr binding capacity may serve as a marker of SCCHN. These subnormal levels of OGFr may diminish the efficacy of the OGF-OGFr axis in maintaining cell proliferative activity, and contribute to more active cell replication. Gene therapy to reinstate more OGFr, and thus enhance OGFr function, could serve as a useful treatment for inhibiting tumor progression.

Related Articles

Journal Cover

June 2006
Volume 28 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
McLaughlin PJ and Zagon IS: Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. Int J Oncol 28: 1577-1583, 2006.
APA
McLaughlin, P.J., & Zagon, I.S. (2006). Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. International Journal of Oncology, 28, 1577-1583. https://doi.org/10.3892/ijo.28.6.1577
MLA
McLaughlin, P. J., Zagon, I. S."Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor". International Journal of Oncology 28.6 (2006): 1577-1583.
Chicago
McLaughlin, P. J., Zagon, I. S."Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor". International Journal of Oncology 28, no. 6 (2006): 1577-1583. https://doi.org/10.3892/ijo.28.6.1577